New Delhi, Sept. 26 -- Continuing his policy of imposing tariffs on imports, US President Donald Trump on Thursday announced 100% duties on branded drugs from 1 October. The move is unlikely to impact India, as the country is a major player in generic medicines and vaccines. Nevertheless, the decision has caused jitters.According to a report by Brickwork Research, innovator or branded drugs make up only about 3-4% of India's formulation market. It is the branded generic products that take the lion's share. This trend has been consistent over the years.







Innovator drugs, or branded drugs, are developed through extensive research and are protected by patents. Branded generics refer to medications that contain the same active ingredien...